Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 December 2018 | Story Leonie Bolleurs | Photo Sonia Small
David Abbey
David Abbey is also serving on the UFS Council’s Finance, Audit, Risk and IT Governance Committee.

David Abbey, a senior banker and transactor in the Acquisition and Leveraged Finance Division at Rand Merchant Bank in Johannesburg, was appointed to the UFS Council.

An undergraduate student of Rhodes University, David is also a proud product of the UFS, having completed his Accounting honours degree at this university. For the past few years, he has also guest lectured on investment banking and financial instruments to Accounting honours students as part of the PwC Financial Instruments Programme.

Large-scale impact

Therefore, his appointment to the Council is particularly special to him.

“Being a member of the Council gives me the platform to have a more large-scale impact on the institution, academic community, the economy, and society. I’m thrilled to be serving alongside an astute body of incredible individuals from whom I will undoubtedly learn,” he says.

Realising his full potential

David is serving on the Council’s Finance, Audit, Risk and IT Governance Committee and his experience in, and knowledge of finance, technology, and audit skills will stand him in good stead. When he’s not developing and structuring innovative, multidisciplinary, and integrated financial solutions for his corporate clients, he loves to be active. He is a regular gym-goer and plays and watches all kinds of sport. Travel, the arts, and motoring are some of his other passions. 

On a personal level, there is still much he wants to achieve. “I want to continue to work hard, using my God-given talents to realise my full potential and to make a humble mark in society and in people’s lives.”

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept